Devyser secures a four-year tender in France for Devyser Compact
Devyser, a leading provider of advanced genetic testing solutions, has been awarded a new tender in...
News | February 2, 2021
Devyser has been awarded a funding of EUR 750,000 through the Eurostars-2 program and will join its efforts with the University Hospital of Zurich to further develop its unique NGS based test for early detection of kidney transplant recipients.
Through this project, Devyser aims to provide a certified CE-IVD kit, including reagents, protocols and software for data analysis ready to implement for routine use.
Link to the full press release:
Devyser receives EUR 750,000 Eurostars grant to develop novel DNA test for early detection of transplant rejection
Devyser, a leading provider of advanced genetic testing solutions, has been awarded a new tender in...
Read More
Devyser is proud to announce that One Lambda Devyser Chimerism and Advyser Chimerism have been...
Read More
Devyser today announced that the Centers for Medicare & Medicaid Services (CMS) has issued its...
Read More
Devyser today announced the enrollment of the first patient in its Devyser Accept cfDNA clinical...
Read More